Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Roger bought ~500,000 shares from 16 to 26¢ last 52 weeks
View:
Post by BuenaSuertaAtod on Feb 03, 2021 9:19am

Roger bought ~500,000 shares from 16 to 26¢ last 52 weeks

This took the CEO's holdings from roughly 6,725,000 to 7,235,000 shares. He bought at least a dozen times.I don't see much activity on the part of other insiders..

Anyone know what the insder holdings amount to in total?
Comment by Bunge on Feb 03, 2021 9:34am
Pretty good to see. Although IF he and his wife still make $300G+ per year combined ($1Million over 3 years) it's not really a hardship putting in another $90G.
Comment by jicoop on Feb 03, 2021 9:37am
Not sure all of them, this is all I can see : Issuer Name Theralase Technologies Inc. Insider Name Anderson, Guy John Relationship as filed with regulators 4 - Director of Issuer Transaction ID 3665139 Filing Date Jan 19, 2021 Transaction Date Jan 18, 2021 Security Type Common Shares Transaction Nature 10 - Acquisition ...more  
Comment by jicoop on Feb 03, 2021 9:49am
Some further digging, I think these are accurate , just the bottom line : Kristina Hachey , 1,616,267 shares Kipton Lad  ,  166,666 shares Matthew Perraton  ,  41,000 shares
Comment by Eoganacht on Feb 03, 2021 11:44am
Excellent! He's actually putting his money where his mouth is. The more he invests the happier I am. He's also buying shares for his kids to ensure their future. I think ex-CEO, Mr. Dumoulin-White is going to be as rich as Croesus and he deserves it.  I'm happy to just go along for the ride.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250